Latest Advances in Lung Cancer Research

On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

New NCCN guidelines help doctors treat lung cancer more effectively with early detection, personalized treatment plans, and comprehensive supportive care recommendations.

AstraZeneca’s Imfinzi shows promise in treating aggressive small cell lung cancer, potentially offering a new, more effective treatment option for this hard-to-treat disease.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki, a new drug for treating HER2-positive unresectable or metastatic breast cancer in adults.

Cancer death rates in the U.S. have dropped 33% since 1991, saving 3.8 million lives, but disparities and challenges in certain cancers remain.

The FDA has approved amivantamab for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

This article reviews strategies for managing treatment resistance in advanced EGFR-mutated lung cancer, focusing on personalization, parsimony, and partnership.

Tepotinib, the first FDA-approved treatment for MET-mutated lung cancer, improves tumor shrinkage and survival.

FDA approves osimertinib plus chemo as first-line treatment for EGFR-mutated lung cancer, improving survival.

Study finds NSCLC patients treated with low-dose radiation & immunotherapy had higher progression-free survival than with immunotherapy alone – combo extended PFS and bolstered immune response.

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Recent studies confirm genomic testing for NSCLC enhances treatment choices and survival, advocating for its standardization in clinical practice.